CF PharmTech, Inc. Stock

2652

CNE1000074R9

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:08 2026-10-09 EDT			5-day change	1st Jan Change
6.055 ^HKD	+5.30%		-11.61%	-82.70%

10-06	109,754,801 Ordinary Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	261,025,586 H Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI

Latest news: CF PharmTech, Inc.

10-06	109,754,801 Ordinary Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	261,025,586 H Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
09-30	Tranche Update on CF PharmTech, Inc.'s Equity Buyback Plan announced on December 30, 2025.	CI
09-28	CF PharmTech, Inc. commences an Equity Buyback Plan for 30,082,658 shares, representing 7.33% of its issued share capital, under the authorization approved on June 26, 2026.	CI
09-22	CF PharmTech Doses First Subject in Phase I Trial for Inhaled Lung Disease Drug	MT
09-21	Cf Pharmtech, Inc. Completes Enrollment and Dosing of First Healthy Volunteer in Phase I Clinical Trial of Icf004	CI
08-31	CF PharmTech, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-24	CF PharmTech, Inc. Announces Expansion of Indications of ICF001 Following Receipt of Implied Clinical Trial Approvals from the NMPA	CI
07-31	CF PharmTech Eyes HK$295 Million from Share Placement	MT
06-26	Cf Pharmtech, Inc. Announces Board and Supervisor Appointments, Effective June 26, 2026	CI
06-25	CF PharmTech, Inc.'s Equity Buyback announced on December 30, 2025, has expired with 1,397,000 shares, representing 0.38% for HKD 35.9 million.	CI
06-05	CF PharmTech Clears GMP Inspection for Suzhou Inhalation Drug Facility	MT
06-04	CF PharmTech, Inc. Inhalation Formulation Production Base Passes GMP Inspection in PIC/S Member Country	CI

More news

Managers and Directors: CF PharmTech, Inc.

Manager	Title	Age	Since
Wen Qing Liang CEO	Chief Executive Officer	60	2006-12-31
Li Li CTO	Chief Tech/Sci/R&D Officer	67	2020-08-31
Wei Wei DFI	Director of Finance/CFO	47	2021-11-14

Director	Title	Age	Since
Li Li BRD	Director/Board Member	67	2020-08-31
Wen Qing Liang CHM	Chairman	60	2006-12-31
Qi Li BRD	Director/Board Member	67	2020-08-31

More insiders

CF PharmTech, Inc. is a China-based company primarily the research and development, production and sale of respiratory drugs and other related medical products. The Companyâ€™s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.

Employees

625

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-09	HK$6.055	+5.30%	10,319,300
26-10-08	HK$5.750	-13.40%	25,334,505
26-10-07	HK$6.640	-3.56%	996,400
26-10-06	HK$6.885	-3.84%	434,100
26-10-05	HK$7.160	+4.53%	625,300

Delayed Quote Hong Kong S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - CF PharmTech, Inc.

Company calendar

Stock Market
Stocks
2652 Stock

As early as today, start finding the best investment opportunities!

Market Cap	2.1B 2.46B 314M 280M 260M 237M 447M 30.34B 449M 3.14B 1.23B 15.47B 1.18B 1.15B 49.65B	P/E 2024 *	-	P/E 2025	4,780x
Enterprise Value	1.59B 1.86B 237M 212M 197M 179M 339M 22.97B 340M 2.37B 930M 11.71B 891M 872M 37.57B	EV / Sales 2024 *	-	EV / Sales 2025	28.8x
Free-Float	60.8%	Yield 2024 *	-	Yield 2025	-

1 day	+5.30%
1 week	-11.61%
Current month	-12.69%
1 month	-36.93%
3 months	-65.40%
6 months	-73.67%
Current year	-82.70%

1 week	5.18	7.3
1 month	5.18	11.49
Current year	5.18	39.5
1 year	5.18	39.5
3 years	5.18	48.8
5 years	5.18	48.8
10 years	5.18	48.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/28/26	Wen Qing Liang	Other	Chief Executive Officer	25,100	0.0077%
9/28/26	Li Li	Other	Founder	25,100	0.0077%
12/22/25	Wen Qing Liang	Other	Chief Executive Officer	6,500	0.0022%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CF PHARMTECH, INC.	+5.30%	-11.61%	-80.42%	-	314M
ELI LILLY AND COMPANY	+0.83%	+3.19%	+41.49%	+103.56%	1,051B
JOHNSON & JOHNSON	+1.93%	+2.11%	+37.08%	+65.09%	630B
ABBVIE INC.	+1.49%	+5.19%	+19.94%	+85.69%	489B
MERCK & CO., INC.	+2.26%	+0.90%	+69.32%	+40.53%	359B
ROCHE HOLDING AG	+1.45%	+3.50%	+23.29%	+41.62%	344B
NOVARTIS AG	+1.17%	+2.37%	+13.47%	+33.64%	272B
ASTRAZENECA PLC	+0.89%	+1.08%	-6.13%	+9.29%	246B
AMGEN INC.	+1.82%	+2.94%	+42.99%	+52.95%	224B
GILEAD SCIENCES, INC.	+2.77%	+4.44%	+29.01%	+98.99%	187B
Average	+1.99%	+1.12%	+19.00%	+59.04%	380.4B
Weighted average by Cap.	+1.47%	+2.44%	+33.35%	+69.01%

CF PharmTech, Inc. Stock

Stocks

2652

CNE1000074R9

Pharmaceuticals

Valuation: CF PharmTech, Inc.

Chart: CF PharmTech, Inc.

Latest news: CF PharmTech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CF PharmTech, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

	2024	2025
Net sales	608M 712M 90.73M 81.04M 75.38M 68.57M 129M 8.78B 130M 907M 355M 4.48B 341M 333M 14.37B	433M 507M 64.57M 57.67M 53.65M 48.8M 92.14M 6.25B 92.53M 646M 253M 3.19B 242M 237M 10.22B
Net income	21.09M 24.71M 3.15M 2.81M 2.62M 2.38M 4.49M 305M 4.51M 31.48M 12.33M 155M 11.82M 11.56M 499M	2.48M 2.91M 371K 331K 308K 280K 529K 35.91M 532K 3.71M 1.45M 18.31M 1.39M 1.36M 58.74M
Net Debt	-275M -322M -41.06M -36.67M -34.11M -31.03M -58.58M -3.97B -58.83M -411M -161M -2.03B -154M -151M -6.5B	-511M -598M -76.24M -68.09M -63.34M -57.61M -109M -7.38B -109M -762M -299M -3.76B -286M -280M -12.07B